ENTX קפיטליזציה חשבונאית Entera Bio Ltd

This price trend chart for Entera Bio Ltd. (ENTX) illustrates the asset's dynamics, with its current value standing at 0.03. Entera Bio Ltd. (ENTX) operates using existing cash reserves, covering research losses from accumulated capital. The business focuses on creating tablet versions of protein-based drugs, monetizing patents through licensing fees from industry behemoths. Drug synthesis is automated via IT algorithms, although final tests require physician oversight.

The successful conversion of injections into oral form directly drives the growth of net assets for Entera Bio Ltd. (ENTX), confirming financial stability amidst high liquidity requirements. This metric measures the real value of the business through the difference between assets and liabilities, allowing investors to assess the risk of capital impairment based on book value capitalization.